Herpes Zoster (Shingles) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Herpes Zoster (Shingles) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Herpes Zoster (Shingles) - Pipeline Review, H2 2016', provides an overview of the Herpes Zoster (Shingles) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
- The report reviews pipeline therapeutics for Herpes Zoster (Shingles) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Herpes Zoster (Shingles) therapeutics and enlists all their major and minor projects
- The report assesses Herpes Zoster (Shingles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Zoster (Shingles) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Zoster (Shingles) - Overview 8
Herpes Zoster (Shingles) - Therapeutics under Development by Companies 9
Herpes Zoster (Shingles) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Herpes Zoster (Shingles) - Products under Development by Companies 14
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development 15
Astellas Pharma Inc. 15
Beijing Minhai Biotechnology Co., Ltd 16
ContraVir Pharmaceuticals, Inc. 17
Epiphany Biosciences, Inc. 18
Foamix Pharmaceuticals Ltd. 19
GeneOne Life Science, Inc. 20
GlaxoSmithKline Plc 21
Merck & Co., Inc. 22
N & N Pharmaceuticals Inc. 23
NAL Pharmaceuticals Ltd. 24
NanoViricides, Inc. 25
ReceptoPharm, Inc. 26
TSRL, Inc. 27
XBiotech Inc 28
Herpes Zoster (Shingles) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
acyclovir - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
amenamevir - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
FV-100 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
GLS-5100 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
GSK-1437173A - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
herpes zoster vaccine - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Monoclonal Antibody for Shingles - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NAL-3221 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NAL-3223 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NN-001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
RPI-78M - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule for Shingles - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
TSR-087 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
V-212 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
valomaciclovir stearate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Herpes Zoster (Shingles) - Dormant Projects 61
Herpes Zoster (Shingles) - Discontinued Products 62
Herpes Zoster (Shingles) - Product Development Milestones 63
Featured News & Press Releases 63
Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM 63
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles 64
Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug 65
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 65
Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over 66
Sep 08, 2015: Clinical trial for Cardiff's shingles treatment 67
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 67
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 68
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied 68
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 69
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 70
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 71
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 71
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles 72
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Herpes Zoster (Shingles), H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H2 2016 15
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 16
Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 17
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H2 2016 18
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 19
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science, Inc., H2 2016 20
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2016 21
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H2 2016 22
Herpes Zoster (Shingles) - Pipeline by N & N Pharmaceuticals Inc., H2 2016 23
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 24
Herpes Zoster (Shingles) - Pipeline by NanoViricides, Inc., H2 2016 25
Herpes Zoster (Shingles) - Pipeline by ReceptoPharm, Inc., H2 2016 26
Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H2 2016 27
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37
Herpes Zoster (Shingles) - Dormant Projects, H2 2016 61
Herpes Zoster (Shingles) - Discontinued Products, H2 2016 62